Lysogene hosts the first European workshop for neuropsychologists to discuss assessment tools in MPS IIIA

Monday, March 16

Seven neuropsychologists and metabolic specialists from six countries met to address specific questions relating to meaningful measures in MPS IIIA on cognition, behaviour, sleep and quality of life. Experts reviewed relevant evidence before selecting clinical outcome assessment tools for the future clinical history study and gene therapy trial.